insulin resistance metabolic syndrome
Conditions
Interventions
Subjects will receive oral vancomycin 500 mg 4 times a day for 7 days.
Gut microbiota
inflammation
platelets.
postprandial period
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Metabolic syndrome patients: * Caucasian male * BMI *30 kg/m2 * At least 2 of the following criteria: o fasting plasma glucose *5.6 mmol/L o waist-circumference *102 cm o HDL-cholesterol *1.02 mmol/L o Blood pressure *130/85 mmHg o HOMA-IR index *2.5 (HOMA-IR is measured as (fasting insulin (pmol/L) x fasting glucose (mmol/L)) / 135) * Triglycerides *1.7 mmol/L * Subjects should be able to give informed consent;Healthy controls: * Caucasian male * BMI 18,5-25 kg/m2 * HOMA-IR index *2.0 * Subjects should be able to give informed consent
Exclusion criteria
Exclusion criteria: Metabolic syndrome patients: * A history of cardiovascular event (CVI, MI) or pacemaker implantation * Use of any medication including PPI and antibiotics in the past three months or during the study period * (Expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count 5 units of alcohol daily or use of alcohol during the study period * History of cholecystectomy;Healthy controls: * A history of cardiovascular event (CVI, MI) or pacemaker implantation * Use of any medication including PPI and antibiotics in the past three months or during the study period * (Expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count 5 units of alcohol daily or use of alcohol during the study period * History of cholecystectomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the effect of oral vancomycin in lean versus obese, insulin resistant subjects on postprandial bacterial translocation, as measured by plasma LPS, LBP and sCD14 as well as 16S DNA concentrations in whole blood, isolated platelets and isolated monocytes. | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate postprandial platelet activation, as measured by P-selectin expression and platelet-monocyte interaction in flow cytometric analyses. All measurements will be related to postprandial inflammation, as measured by monocyte phenotyping using flow cytrometric and histopathological analyses and plasma cytokine concentrations, and gut microbiota composition before and after treatment with oral vancomycin. Moreover, we will assess postprandial concentrations of plasma bile acids, FGF-19 and glucagon-like peptide 1 (GLP-1). Finally, we will determine the effect of oral vancomycin on satiety as measured by time taken to eat a standardized meal and intestinal transit time as measured by 24 hour Sitzmark capsule clearance. | — |
Countries
The Netherlands
Outcome results
None listed